Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59


Gefitinib is effective against juvenile pilocytic astrocytoma in vitro.

Foreman NK, Gore L, Wells D, Straessle J, Heideman R, Donson AM.

Pediatr Blood Cancer. 2006 Sep;47(3):293-8.


Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.

Clin Cancer Res. 2004 Oct 1;10(19):6487-501.


Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.

Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA Jr.

Clin Cancer Res. 2006 Dec 1;12(23):7117-25.


Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo.

Meco D, Servidei T, Riccardi A, Ferlini C, Cusano G, Zannoni GF, Giangaspero F, Riccardi R.

Neuro Oncol. 2009 Jun;11(3):250-9. doi: 10.1215/15228517-2008-095. Epub 2008 Nov 25.


Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.

Van Schaeybroeck S, Karaiskou-McCaul A, Kelly D, Longley D, Galligan L, Van Cutsem E, Johnston P.

Clin Cancer Res. 2005 Oct 15;11(20):7480-9.


EGFR inhibition using gefitinib is not active in neuroblastoma cell lines.

Rössler J, Odenthal E, Geoerger B, Gerstenmeyer A, Lagodny J, Niemeyer CM, Vassal G.

Anticancer Res. 2009 Apr;29(4):1327-33.


Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.

Cancer Res. 2004 Aug 1;64(15):5355-62.


Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines.

Carrasco-García E, Saceda M, Grasso S, Rocamora-Reverte L, Conde M, Gómez-Martínez A, García-Morales P, Ferragut JA, Martínez-Lacaci I.

Exp Cell Res. 2011 Jun 10;317(10):1476-89. doi: 10.1016/j.yexcr.2011.03.015. Epub 2011 Apr 1.


Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.

Pino MS, Shrader M, Baker CH, Cognetti F, Xiong HQ, Abbruzzese JL, McConkey DJ.

Cancer Res. 2006 Apr 1;66(7):3802-12. Erratum in: Cancer Res. 2010 Jan 15;70(2):852-3.


Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours.

Jacob K, Albrecht S, Sollier C, Faury D, Sader E, Montpetit A, Serre D, Hauser P, Garami M, Bognar L, Hanzely Z, Montes JL, Atkinson J, Farmer JP, Bouffet E, Hawkins C, Tabori U, Jabado N.

Br J Cancer. 2009 Aug 18;101(4):722-33. doi: 10.1038/sj.bjc.6605179. Epub 2009 Jul 14.


[Effect of gefitinib on radiosensitivity of gastric cancer cell lines].

Cao WG, Ma T, Li JF, Li H, Ji YB, Chen XH, Liu BY, Jin YN.

Ai Zheng. 2007 Dec;26(12):1330-5. Chinese.


Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.

Van Schaeybroeck S, Kyula J, Kelly DM, Karaiskou-McCaul A, Stokesberry SA, Van Cutsem E, Longley DB, Johnston PG.

Mol Cancer Ther. 2006 May;5(5):1154-65.


Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib.

Taguchi T, Tsukuda M, Imagawa-Ishiguro Y, Kato Y, Sano D.

Oncol Rep. 2008 Jan;19(1):65-71.


Gefitinib (Iressa) potentiates the effect of ionizing radiation in thyroid cancer cell lines.

Lopez JP, Wang-Rodriguez J, Chang CY, Sneh G, Yu MA, Pardo FS, Aguilera J, Ongkeko WM.

Laryngoscope. 2008 Aug;118(8):1372-6. doi: 10.1097/MLG.0b013e318172aae4.


Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.

Dong S, Zhang XC, Cheng H, Zhu JQ, Chen ZH, Zhang YF, Xie Z, Wu YL.

Cancer Chemother Pharmacol. 2012 Nov;70(5):707-16. doi: 10.1007/s00280-012-1946-3. Epub 2012 Sep 2.


The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.

Shen L, Li Z, Shen S, Niu X, Yu Y, Li Z, Liao M, Chen Z, Lu S.

Lung Cancer. 2012 Dec;78(3):193-200. doi: 10.1016/j.lungcan.2012.08.012. Epub 2012 Sep 15.


Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase.

Okabe T, Okamoto I, Tsukioka S, Uchida J, Iwasa T, Yoshida T, Hatashita E, Yamada Y, Satoh T, Tamura K, Fukuoka M, Nakagawa K.

Mol Cancer Ther. 2008 Mar;7(3):599-606. doi: 10.1158/1535-7163.MCT-07-0567.

Supplemental Content

Support Center